Anti-IgE catalytic antibody - Abgenix

Drug Profile

Anti-IgE catalytic antibody - Abgenix

Alternative Names: IgE-CA

Latest Information Update: 21 Feb 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abgenix
  • Class Catalytic antibodies
  • Mechanism of Action Immunoglobulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypersensitivity

Most Recent Events

  • 30 Jun 2004 Discontinued - Preclinical for Allergy in USA (unspecified route)
  • 14 Feb 2002 Hesed Biomed has been acquired by Abgenix
  • 13 Apr 2000 IgE-CA is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top